SLC5A2 and atrial fibrillation: Given the decreased risk of major adverse cardiovascular events as seen with the use of GLP-1RA and SGLT-2 inhibitors, additional studies are urgently needed for newer classes of diabetes medications to assess the incidence of AF through potential interactions between oxidative stress, atrial fibrosis, and autonomic remodeling.